Overview of the Lenograstim Pharmacoeconomics Programme
- 1 January 1994
- journal article
- review article
- Published by Springer Nature in PharmacoEconomics
- Vol. 6 (2) , 9-17
- https://doi.org/10.2165/00019053-199400062-00004
Abstract
No abstract availableKeywords
This publication has 20 references indexed in Scilit:
- Placebo-controlled phase III trial of lenograstim in bone-marrow transplantationThe Lancet, 1994
- Pharmacoeconomic Evaluation of LenograstimPharmacoEconomics, 1994
- Economic Evaluation of Lenograstim for Prophylaxis of Chemotherapy-Induced Neutropenia in Patients with Small Cell Lung CancerPharmacoEconomics, 1994
- Economic Analysis of Lenograstim in the Correction of Neutropenia Following Chemotherapy for Non-Hodgkinʼs LymphomaPharmacoEconomics, 1994
- Economic Evaluation of Lenograstim (Glycosylated rHuG-CSF) in the Treatment of Inflammatory Breast Cancer for Germany and ItalyPharmacoEconomics, 1994
- Methodological Issues in Economic Assessments of New TherapiesPharmacoEconomics, 1994
- Granulocyte Colony-Stimulating Factor and Granulocyte-Macrophage Colony-Stimulating FactorNew England Journal of Medicine, 1992
- From the Infectious Diseases Society of America: Guidelines for the Use of Antimicrobial Agents in Neutropenic Patients with Unexplained FeverThe Journal of Infectious Diseases, 1990
- Hematopoietic Growth FactorsNew England Journal of Medicine, 1989
- After Empiric Therapy: What To Do Until the Granulocyte Comes BackClinical Infectious Diseases, 1987